246 related articles for article (PubMed ID: 17471171)
1. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
2. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V
J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
Palermo B; Del Bello D; Sottini A; Serana F; Ghidini C; Gualtieri N; Ferraresi V; Catricalà C; Belardelli F; Proietti E; Natali PG; Imberti L; Nisticò P
Cancer Res; 2010 Sep; 70(18):7084-92. PubMed ID: 20823160
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
10. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC; Harlin H; Gajewski TF
J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
[TBL] [Abstract][Full Text] [Related]
11. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
13. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
15. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
Lienard D; Avril MF; Le Gal FA; Baumgaertner P; Vermeulen W; Blom A; Geldhof C; Rimoldi D; Pagliusi S; Romero P; Dietrich PY; Corvaia N; Speiser DE
J Immunother; 2009 Oct; 32(8):875-83. PubMed ID: 19752746
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
[TBL] [Abstract][Full Text] [Related]
18. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
19. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.
Pittet MJ; Speiser DE; Liénard D; Valmori D; Guillaume P; Dutoit V; Rimoldi D; Lejeune F; Cerottini JC; Romero P
Clin Cancer Res; 2001 Mar; 7(3 Suppl):796s-803s. PubMed ID: 11300475
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]